Walter J. Liszewski, MD: Mechanisms of Action in Prurigo Nodularis

May 11, 2026

Walter J. Liszewski, MD, an associate professor of dermatology at Northwestern University, discusses mechanisms of action to consider for treatment of patients with prurigo nodularis. This includes the mechanism of action for dupilumab (Dupixent) and nemolizumab (Nemluvio). He also discusses the significant inflammatory component involving keratinocytes, nerves, and inflammatory cells that prurigo nodularis presents. He notes the effectiveness of the currently available biologic nemolizumab in alleviating itch quickly, though improvements in lesions and scars can take longer. There are new drugs in development as well for this patient population, according to Dr. Liszewski.

Topics Covered:

Current FDA-approved treatments for prurigo nodularis
Impact of itch on patients’ lives
New drugs in development for prurigo nodularis

MORE EXPERT PERSPECTIVES IN PRURIGO NODULARIS:

Angela Lamb, MD: Breaking the Itch-Scratch Cycle in Prurigo Nodularis

Angela Lamb, MD, an associate professor of dermatology at the Icahn School of Medicine at Mount Sinai in New York, discusses recent advancements in understanding

David Cotter, MD, PhD: Patient Presentation and Clinical Trial Data for Prurigo Nodularis

Dr. Cotter, a board-certified dermatologist at Las Vegas Dermatology, presents a real-world case of Prurigo Nodularis, highlighting both the severity of disease presentation and the

Jenny Murase, MD: Assessing Symptoms and Presentation of Patients with Prurigo Nodularis

Dr. Murase reviews the clinical presentation of Prurigo Nodularis, a chronic inflammatory skin condition characterized by intensely pruritic nodules and significant disease burden. She outlines

James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

Drs. Del Rosso and Cotter discuss how advances in the molecular understanding of Prurigo Nodularis have led to the development of targeted therapies that address

Diego Ruiz Dasilva, MD, FAAD: Providing Treatment for Challenging Cases of Chronic Pruritus

Dr. Dasilva presents findings from a real-world case series evaluating treatment options for patients with treatment-resistant chronic pruritus, highlighting the marked efficacy of Nemolizumab. His

JCAD Archives